Alcon's Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease - Seite 3

Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such as "can," "to be presented," "introduce," "will," "followed by," or similar terms, or regarding potential future revenues from Simbrinza. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Simbrinza will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Simbrinza will be commercially successful in the future. In particular, management's expectations regarding Simbrinza could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Alcon
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. The three Alcon businesses - Surgical, Ophthalmic Pharmaceuticals and Vision Care - offer the widest spectrum of eye care products in the world. Alcon is the second largest division of the Novartis Group with sales of USD 10.5 billion in 2013. Headquartered in Fort Worth, Texas, USA, Alcon has more than 25,000 employees worldwide, operations in 75 countries and products available in 180 markets. For more information, visit www.alcon.com.